TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
GILD

Gilead Sciences Inc

Healthcare · Drug Manufacturers - General

150.10$ -0.5% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios GILD
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Valuation
12.8 8.5 7.2 20.4 15.0 15.4 598.6 14.7 23.6 18.0 241.6 18.1
6.2 4.7 3.2 3.6 3.7 3.7 3.0 3.4 4.0 3.8 4.0 5.2
9.8 8.1 5.0 4.6 3.8 3.7 4.0 4.3 5.1 4.5 6.0 6.8
6.3 5.0 3.8 4.6 4.1 4.3 4.0 4.1 4.7 4.5 4.6 5.8
9.6 6.9 6.1 7.6 8.9 12.7 24.0 10.0 14.5 15.9 29.9 12.6
12.7 7.5 6.0 8.4 11.0 10.0 9.8 8.5 13.0 13.7 11.3 16.3
7.9% 13.3% 16.8% 12.0% 9.1% 10.0% 10.2% 11.8% 7.7% 7.3% 8.9% 6.1%
Margins
84.8% 87.7% 86.0% 83.3% 78.1% 79.2% 81.5% 75.8% 79.3% 100.0% 78.3% 78.8%
61.3% 68.0% 58.0% 54.1% 37.1% 19.1% 16.5% 36.3% 26.9% 28.0% 5.8% 39.7%
48.6% 55.5% 44.4% 17.7% 24.7% 24.0% 0.5% 22.8% 16.8% 20.9% 1.7% 28.9%
49.3% 62.8% 53.6% 43.3% 33.8% 37.1% 30.5% 39.6% 30.6% 27.4% 35.8% 32.1%
Returns
76.5% 94.7% 69.7% 22.6% 25.5% 23.9% 0.7% 29.5% 21.6% 24.8% 2.5% 37.5%
34.9% 34.9% 23.7% 6.6% 8.6% 8.7% 0.2% 9.2% 7.3% 9.1% 0.8% 14.4%
Balance Sheet & Debt
1,909 8,346 19,525 25,954 9,382 12,962 25,405 21,357 19,818 18,902 16,720 17,372
0.1 0.4 1.0 1.6 0.9 1.7 6.1 1.9 2.2 2.5 3.8 1.3
45.6% 36.9% 34.0% 29.1% 33.6% 36.6% 26.6% 31.0% 33.6% 36.8% 32.8% 38.5%
0.8 1.1 1.4 1.6 1.3 1.1 1.7 1.3 1.2 1.1 1.4 1.1
Per Share
7.35 11.91 9.94 3.51 4.17 4.22 0.10 4.93 3.64 4.50 0.38 6.78
15.11 21.46 22.38 19.79 16.92 17.58 19.55 21.64 21.62 21.55 22.91 23.46
9.60 12.57 14.26 15.50 16.35 17.64 14.41 16.69 16.83 18.15 15.40 18.09
7.44 13.48 12.00 8.57 5.72 6.51 5.95 8.56 6.61 5.90 8.21 7.53

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?